{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:12:01Z","timestamp":1785888721630,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_170249"],"award-info":[{"award-number":["320030_170249"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_185111"],"award-info":[{"award-number":["32003B_185111"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. There are no pharmacogenetic studies on LSD. In vitro metabolic studies indicate that several cytochrome P450 (CYP) isoforms (e.g., CYP2D6, CYP1A2, and CYP2C9) are involved in LSD metabolism, but in vivo data are scarce. The present study examined the influence of genetic polymorphisms of CYP genes on the pharmacokinetics and acute effects of LSD in healthy subjects. We identified common genetic variants of CYPs (CYP2D6, CYP1A2, CYP2C9, CYP2C19, and CYP2B6) in 81 healthy subjects who were pooled from four randomized, placebo-controlled, double-blind Phase 1 studies. We found that genetically determined CYP2D6 functionality significantly influenced the pharmacokinetics of LSD. Individuals with no functional CYP2D6 (i.e., poor metabolizers) had longer LSD half-lives and approximately 75% higher parent drug and main metabolite 2-oxo-3-hydroxy LSD area-under-the-curve blood plasma concentrations compared with carriers of functional CYP2D6. Non-functional CYP2D6 metabolizers also exhibited greater alterations of mind and longer subjective effect durations in response to LSD compared with functional CYP2D6 metabolizers. No effect on the pharmacokinetics or acute effects of LSD were observed with other CYPs. These findings indicate that genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD. Given the potential therapeutic use of psychedelics, including LSD, the role of pharmacogenetic tests prior to LSD-assisted psychotherapy needs to be further investigated.<\/jats:p>","DOI":"10.1038\/s41598-021-90343-y","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T10:03:15Z","timestamp":1621936995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Patrick","family":"Vizeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Straumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Dolder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"90343_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57\u201368 (2015).","journal-title":"J. Psychopharmacol."},{"key":"90343_CR2","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/npp.2017.86","volume":"42","author":"ME Liechti","year":"2017","unstructured":"Liechti, M. E. Modern clinical research on LSD. Neuropsychopharmacology 42, 2114\u20132127 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"90343_CR3","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1021\/acschemneuro.8b00043","volume":"9","author":"DE Nichols","year":"2018","unstructured":"Nichols, D. E. Dark classics in chemical neuroscience: Lysergic acid diethylamide (LSD). ACS Chem. Neurosci. 9, 2331\u20132343 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"90343_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611\u2013624 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"90343_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","volume":"64","author":"MP Bogenschutz","year":"2016","unstructured":"Bogenschutz, M. P. & Johnson, M. W. Classic hallucinogens in the treatment of addictions. Prog. Neuropsychopharmacol. Biol. Psychiatry. 64, 250\u2013258 (2016).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"90343_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120959604","author":"Y Schmid","year":"2020","unstructured":"Schmid, Y., Gasser, P., Oehen, P. & Liechti, M. E. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J. Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881120959604 (2020).","journal-title":"J. Psychopharmacol."},{"key":"90343_CR7","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1007\/s00216-018-1558-9","volume":"411","author":"L Wagmann","year":"2019","unstructured":"Wagmann, L. et al. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal. Bioanal. Chem. 411, 4751\u20134763 (2019).","journal-title":"Anal. Bioanal. Chem."},{"key":"90343_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","volume":"164","author":"D Luethi","year":"2019","unstructured":"Luethi, D., Hoener, M. C., Krahenbuhl, S., Liechti, M. E. & Duthaler, U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem. Pharmacol. 164, 129\u2013138 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"90343_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00898.x","volume":"47","author":"C Sachse","year":"1999","unstructured":"Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Functional significance of a C\u2192A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445\u2013449 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"90343_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks, J. K. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93, 402\u2013408 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR11","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284\u2013295 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"90343_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks, J. K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98, 127\u2013134 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/09540261.2013.825581","volume":"25","author":"A Gaedigk","year":"2013","unstructured":"Gaedigk, A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry. 25, 534\u2013553 (2013).","journal-title":"Int. Rev. Psychiatry."},{"key":"90343_CR14","doi-asserted-by":"publisher","first-page":"e82562","DOI":"10.1371\/journal.pone.0082562","volume":"8","author":"SC Preissner","year":"2013","unstructured":"Preissner, S. C. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS ONE 8, e82562 (2013).","journal-title":"PLoS ONE"},{"key":"90343_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","volume":"27","author":"P Vizeli","year":"2017","unstructured":"Vizeli, P., Schmid, Y., Prestin, K., Meyer zu Schwabedissen, H. E. & Liechti, M. E. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur. Neuropsychopharmacol. 27, 232\u2013238 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"90343_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FPC.0000000000000231","volume":"26","author":"Y Schmid","year":"2016","unstructured":"Schmid, Y. et al. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. Pharmacogenet. Genom. 26, 397\u2013401 (2016).","journal-title":"Pharmacogenet. Genom."},{"key":"90343_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze, F. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46, 537\u2013544 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"90343_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/cpt.2057","volume":"109","author":"F Holze","year":"2021","unstructured":"Holze, F. et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin. Pharmacol. Ther. 109, 658\u2013666 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR19","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/bcp.13918","volume":"85","author":"F Holze","year":"2019","unstructured":"Holze, F. et al. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br. J. Clin. Pharmacol. 85, 1474\u20131483 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"90343_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 8, 974 (2017).","journal-title":"Front. Pharmacol."},{"key":"90343_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"90343_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol. 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"key":"90343_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths, R., Richards, W., Johnson, M., McCann, U. & Jesse, R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 22, 621\u2013632 (2008).","journal-title":"J. Psychopharmacol."},{"key":"90343_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","volume":"235","author":"Y Schmid","year":"2018","unstructured":"Schmid, Y. & Liechti, M. E. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology 235, 535\u2013545 (2018).","journal-title":"Psychopharmacology"},{"key":"90343_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid, Y. et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol. Psychiatry. 78, 544\u2013553 (2015).","journal-title":"Biol. Psychiatry."},{"key":"90343_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","volume":"56","author":"PC Dolder","year":"2017","unstructured":"Dolder, P. C. et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin. Pharmacokinetics. 56, 1219\u20131230 (2017).","journal-title":"Clin. Pharmacokinetics."},{"key":"90343_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze, F. et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45, 462\u2013471 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"90343_CR28","doi-asserted-by":"publisher","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus, E., Gamma, A., Kometer, M. & Vollenweider, F. X. Prediction of psilocybin response in healthy volunteers. PLoS ONE 7, e30800 (2012).","journal-title":"PLoS ONE"},{"key":"90343_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser, P. et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J. Nerv. Ment. Dis. 202, 513\u2013520 (2014).","journal-title":"J. Nerv. Ment. Dis."},{"issue":"Suppl 2","key":"90343_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2), 80\u201384 (1998).","journal-title":"Pharmacopsychiatry"},{"key":"90343_CR31","doi-asserted-by":"publisher","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5, e12412 (2010).","journal-title":"PLoS ONE"},{"key":"90343_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk, A. et al. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234\u2013242 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/clpt.2011.287","volume":"91","author":"KR Crews","year":"2012","unstructured":"Crews, K. R. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91, 321\u2013326 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle, K. E. et al. Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci. 13, 116\u2013124 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"90343_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1248\/bpb.19.1103","volume":"19","author":"Y Hashimoto","year":"1996","unstructured":"Hashimoto, Y. et al. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol. Pharm. Bull. 19, 1103\u20131105 (1996).","journal-title":"Biol. Pharm. Bull."},{"key":"90343_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/clpt.2008.10","volume":"84","author":"BF Gage","year":"2008","unstructured":"Gage, B. F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326\u2013331 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR37","volume-title":"ALFA: Allele Frequency Aggregator","author":"L Phan","year":"2020","unstructured":"Phan, L. et al. ALFA: Allele Frequency Aggregator. National Center for Biotechnology Information, U. S. National Library of Medicine. www.ncbi.nlm.nih.gov\/snp\/docs\/gsr\/alfa\/ (2020)."},{"key":"90343_CR38","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (2019)."},{"key":"90343_CR39","first-page":"072","volume":"19","author":"PC Dolder","year":"2015","unstructured":"Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M. & Liechti, M. E. Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int. J. Neuropsychopharmacol. 19, 072 (2015).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"90343_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/dta.2042","volume":"9","author":"AE Steuer","year":"2017","unstructured":"Steuer, A. E. et al. Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS\/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Test Anal. 9, 788\u2013797 (2017).","journal-title":"Drug Test Anal."},{"key":"90343_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/00912700022008702","volume":"40","author":"CL Alfaro","year":"2000","unstructured":"Alfaro, C. L., Lam, Y. W., Simpson, J. & Ereshefsky, L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. J. Clin. Pharmacol. 40, 58\u201366 (2000).","journal-title":"J. Clin. Pharmacol."},{"key":"90343_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1176\/appi.ajp.158.1.78","volume":"158","author":"JH Meyer","year":"2001","unstructured":"Meyer, J. H. et al. The effect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Am. J. Psychiatry. 158, 78\u201385 (2001).","journal-title":"Am. J. Psychiatry."},{"key":"90343_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"KR Bonson","year":"1996","unstructured":"Bonson, K. R., Buckholtz, J. W. & Murphy, D. L. Chronic administration of serotnergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14, 425\u2013436 (1996).","journal-title":"Neuropsychopharmacology"},{"key":"90343_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/clpt.2014.129","volume":"96","author":"AN Werk","year":"2014","unstructured":"Werk, A. N. & Cascorbi, I. Functional gene variants of CYP3A4. Clin. Pharmacol. Ther. 96, 340\u2013348 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90343_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/00221309.1994.9921213","volume":"121","author":"DW Zimmerman","year":"1994","unstructured":"Zimmerman, D. W. A note on the influence of outliers on parametric and nonparametric tests. J. Gen. Psychol. 121, 391\u2013401 (1994).","journal-title":"J. Gen. Psychol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90343-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:34:58Z","timestamp":1670056498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90343-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90343"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90343-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.E.L. is a consultant for Mind Medicine, Inc. The other authors declare no conflicts of interests. Knowhow and data that are associated with this work and owned by the University Hospital Basel were licensed by Mind Medicine, Inc., after study completion. Mind Medicine, Inc., had no role in financing, planning, or conducting the present study or the present publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10851"}}